GnRH Antagonist Protects Ovarian Function During Chemotherapy
August 2, 2007
Source: 23rd Annual Conference of the European Society of Human Reproduction and Embryology, 1-4 July 2007, Lyon, France
&ot&uot
Kate Stern
REFERENCE: O-144 KATE STERN, Royal Women’s Hospital, Melbourne
A potential new way of preserving ovarian function during chemotherapy for cancer could be treatment with an antagonist of gonadotropin-releasing hormone: GnRH. A pilot study from Melbourne looked at 18 young women with cancer or auto immune disease due to receive cyclophosphamide therapy. Sarah Maxwell spoke with Kate Stern and heard more about the study.
[...] study from Melbourne looked at 18 young women with cancer or auto … article continues at admin brought to you by cancer.medtrials.info and [...]